STOCK TITAN

INSM insider/trustee sales include 129,805-share block; new 6,865-share Rule 144 filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Insmed, Inc. (INSM) filed a Form 144 proposing the sale of 6,865 common shares under Rule 144, with an approximate aggregate market value of $881,244, to be sold through Merrill Lynch on NASDAQ on 08/18/2025. The filing states those shares were acquired on 08/18/2025 through stock plan activity and lists prior sales by the same account (William Lewis and William Lewis TTEE) totaling multiple transactions from 05/20/2025 through 08/04/2025, including a large sale of 129,805 shares on 06/16/2025 generating $13,027,678. The notice includes the standard Rule 144 attestation that the seller is not aware of undisclosed material adverse information.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine Rule 144 sale tied to stock-plan issuance; recent aggregated insider sales are notable but not conclusive.

The filing documents a planned sale of 6,865 shares acquired via a stock plan on the same date as the proposed sale, filed to comply with Rule 144. The historical sales log shows frequent dispositions by the same beneficial holder or trustee across May–August 2025, including a material block of 129,805 shares on 06/16/2025 that produced $13,027,678. These patterns can affect supply dynamics but the filing contains no financial results or forward-looking statements; impact appears neutral absent additional company context.

TL;DR: Multiple recent insider/trustee sales, including a large block, raise governance and signaling concerns.

The record of repeated sales by William Lewis and William Lewis TTEE within a short window, culminating in a large 129,805-share sale, could be viewed negatively by investors as insider liquidity events. The Form 144 shows the new 6,865-share sale stems from stock plan activity, but frequent dispositions by related parties warrant scrutiny of insider motivations and lock-up or plan schedules. The filing does not provide explanations or company disclosures to mitigate potential investor concerns.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Insmed Inc

NASDAQ:INSM

INSM Rankings

INSM Latest News

INSM Latest SEC Filings

INSM Stock Data

35.52B
210.98M
0.65%
101.25%
5%
Biotechnology
Pharmaceutical Preparations
Link
United States
BRIDGEWATER